



# Get more answers from a single sample

**A 3-in-1 antigen assay for COVID-19,  
Flu A and Flu B<sup>†</sup>.**

Reliable multiplex results in 15 minutes or less.\*

BD Veritor™ Plus System streamlines clinical and patient workflows by detecting three major respiratory illnesses in one test, reducing the need for multiple sample collections. With multiple testing modes and workflow efficiencies, the analyzer empowers convenience and efficiency.



Learn more at [bdveritor.com](https://bdveritor.com)



## Portable and rapid point-of-care respiratory testing

Diagnose and differentiate between COVID-19, Flu A and Flu B with a single sample.



### Simplifies the testing process

May reduce manual test processing errors with easy operations and single-button functionality.



### Delivers workflow efficiency

Adapts easily to your workflow by offering 2 operational modes

- **Walk Away:** Selected by double-clicking the power button, insert the test device into the Analyzer immediately after the sample has been added. The Analyzer will incubate for the appropriate time for each assay then perform the analysis and display the test result allowing staff to perform other duties while the sample incubates.
- **Analyze Now:** The test device is inserted into the Analyzer after the recommended incubation time for each assay is complete. Allowing for specimens to be processed in batches. The Analyzer then performs the analysis and displays the test result.



### Achieves reliable, rapid results

Displays easy-to-read digital results for COVID-19 and Flu A+B<sup>†</sup> in 15 minutes or less.\*



### Provides results traceability

Captures or downloads the lot number, patient/specimen ID, operator ID, and test records using the BD Veritor™ InfoWiFi module

Contact your authorized distributor partner or BD to learn more.  
For expedited service, say **Veritor** at the prompt. **1.844.823.5433**

\*Result processing times for each BD Veritor™ assay are 15 minutes for the SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays, 10 minutes for Flu A+B and RSV assays, and 5 minutes for the Group A Strep assay.

**†For SARS-CoV-2:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

**†For SARS-CoV-2 & FLU A+B:** In the USA, the BD Veritor™ System for Rapid Detection of SARS-CoV-2 has not been FDA cleared or approved but has been authorized by the FDA under an Emergency Use Authorization for use by authorized laboratories; use by laboratories certified under the CLIA, 42 U.S.C. §263a, that meet requirements to perform moderate, high, or waived complexity tests. The product is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and, in the USA, the emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. §360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152, U.S.  
1.800.638.8663

[bd.com](https://www.bd.com)

